Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Puma Biotechnology (PBYI) Share Price
Media stories about Puma Biotechnology (NYSE:PBYI) have been trending somewhat positive recently, according to Accern. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Puma Biotechnology earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.5022266897315 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- Puma Biotechnology Inc (PBYI) Moves 0.94% – Evergreen Caller (evergreencaller.com)
- At a Pivot Point? Share Update on Lancaster Colony Corporation (NASDAQ:LANC) and Puma Biotechnology, Inc … – FLBC News (flbcnews.com)
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) – Business Wire (press release) (businesswire.com)
- Puma Biotechnology : Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (4-traders.com)
Puma Biotechnology (NYSE:PBYI) opened at 85.15 on Tuesday. Puma Biotechnology has a 52-week low of $28.35 and a 52-week high of $98.85. The stock’s 50 day moving average is $86.87 and its 200-day moving average is $59.81. The firm’s market capitalization is $3.17 billion.
Puma Biotechnology (NYSE:PBYI) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.32) by $0.78. Equities analysts expect that Puma Biotechnology will post ($8.68) earnings per share for the current year.
A number of brokerages have weighed in on PBYI. Stifel Nicolaus reaffirmed a “buy” rating and set a $110.00 price target (down from $118.00) on shares of Puma Biotechnology in a research report on Thursday, August 10th. BidaskClub cut shares of Puma Biotechnology from a “buy” rating to a “hold” rating in a research report on Wednesday, August 16th. Citigroup Inc. raised shares of Puma Biotechnology to a “buy” rating and set a $105.00 price target on the stock in a research report on Sunday, May 28th. J P Morgan Chase & Co set a $105.00 price target on shares of Puma Biotechnology and gave the company a “buy” rating in a research report on Wednesday, August 9th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $125.00 price target on shares of Puma Biotechnology in a research report on Wednesday, August 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $109.56.
In other news, SVP Richard Paul Bryce sold 1,998 shares of the company’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $94.48, for a total transaction of $188,771.04. Following the completion of the sale, the senior vice president now directly owns 27,246 shares in the company, valued at approximately $2,574,202.08. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Adage Capital Partners Gp, L.L sold 507,128 shares of the company’s stock in a transaction on Monday, June 5th. The shares were sold at an average price of $87.84, for a total value of $44,546,123.52. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 774,561 shares of company stock valued at $66,278,386. Corporate insiders own 22.70% of the company’s stock.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Stock Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related stocks with our FREE daily email newsletter.